Shattuck Labs Launched Phase 2 Hidradenitis Trial

The clinical trial will test the efficacy of SL-325 in patients with moderate to severe hidradenitis suppurativa.

Updated on Oct. 1, 2026 in Healthcare

Shattuck Labs Launched Phase 2 Hidradenitis Trial

Live Poll

Do you trust pharmaceutical companies to prioritize patient health over corporate profit when developing new drugs?

Shattuck Labs has initiated plans for a Phase 2 trial of its candidate SL-325 for treating hidradenitis suppurativa, a disease impacting approximately 1% of the global population. The company also appointed Shoba Ravichandran as Senior Vice President of Clinical Development to oversee the program.

Why it matters

The development targets DR3 expression in inflammatory lesions, a pathway linked to the progression of this chronic skin condition. Success in this trial could establish a new treatment pipeline for a demographic that currently has limited therapeutic options.

The RECEPTIVE-HS1 trial will enroll 150 patients, with primary endpoints measured after a 16-week placebo-controlled period. Shattuck Labs reports that existing cash is sufficient to maintain operations into 2029.

The players

Shattuck Labs

A clinical-stage biotechnology company that focuses on the development of novel therapeutics for the treatment of cancer and inflammatory diseases.

Shoba Ravichandran

The newly appointed Senior Vice President of Clinical Development at Shattuck Labs who possesses over 20 years of experience in drug development.

The details

The RECEPTIVE-HS1 study follows a randomized, double-blind, placebo-controlled structure to evaluate SL-325 in patients presenting with five or more abscesses and inflammatory nodules. Trial participants will be split into low-dose, high-dose, and placebo cohorts, with success measured by the proportion of patients achieving HiSCR50 at the 16-week mark. An extension period will continue monitoring through Week 52 to gauge long-term safety and results.

The IND submission for the trial is scheduled for October 2026.
The RECEPTIVE-HS1 Phase 2 clinical trial is expected to initiate in 2026.
Clinical trial primary and secondary endpoints are assessed at Week 16.
The trial extension period concludes at Week 52.
Clinical trial data disclosure is expected in the first half of 2028.

Market Landscape

Shattuck Labs' trial path mirrors standard industry practices for moving protein-based therapeutics through the FDA IND submission requirements. This approach aligns with broader biotech efforts to address chronic inflammatory conditions where existing biological pathways remain highly targeted.

Operators in the biotech sector should track the 2028 data disclosure as a signal for the efficacy of DR3-targeting therapeutics. Management should monitor the impact of this drug development timeline on the company's long-term cash runway and capital allocation.

The takeaway

Shattuck Labs is advancing a novel treatment for a condition that affects roughly 1% of the global population. Stakeholders should track the October 2026 IND submission as the next critical milestone for the company's research roadmap.